These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19171109)

  • 21. Global safety of coxibs and NSAIDs.
    Pham K; Hirschberg R
    Curr Top Med Chem; 2005; 5(5):465-73. PubMed ID: 15974941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?
    Richette P; Latourte A; Frazier A
    Expert Opin Drug Saf; 2015 Aug; 14(8):1259-68. PubMed ID: 26134750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C
    Curr Cardiol Rep; 2016 Mar; 18(3):25. PubMed ID: 26841787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
    Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal toxicity of over-the-counter analgesics.
    Dajani EZ
    Am J Gastroenterol; 1998 Jul; 93(7):1020-2. PubMed ID: 9672322
    [No Abstract]   [Full Text] [Related]  

  • 31. [Problems of cardiovascular toxicity of coxibs and non-selective NSA].
    Forejtová S
    Vnitr Lek; 2006; 52(7-8):677-85. PubMed ID: 16967608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Emery P; Moore A; Hawkey C
    Lancet; 2005 Apr 30-May 6; 365(9470):1538. PubMed ID: 15866301
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular adverse effects of coxibs.
    Prescrire Int; 2002 Dec; 11(62):181-2. PubMed ID: 12472094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
    Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of Vioxx.
    Nyberg J
    Lancet; 2005 Jan 1-7; 365(9453):24-5; author reply 26-7. PubMed ID: 15639670
    [No Abstract]   [Full Text] [Related]  

  • 37. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
    Harris SI; Kuss M; Hubbard RC; Goldstein JL
    Clin Ther; 2001 Sep; 23(9):1422-8. PubMed ID: 11589257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
    McGettigan P; Henry D
    PLoS Med; 2011 Sep; 8(9):e1001098. PubMed ID: 21980265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.